Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial

References

• Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–1290.
   PubMed Web of Science ®Google Scholar
• Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. Jco. 2007;25:431–436.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Hakama M, Knekt P, et al. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594–1598.
   PubMed Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289–294.
   PubMed Web of Science ®Google Scholar
• Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374–383.
   PubMedGoogle Scholar
• Heijnsdijk EA, der Kinderen A, Wever EM, et al. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer. 2009;101:1833–1838.
   PubMed Web of Science ®Google Scholar
• Carlsson S, Leapman M, Carroll P, et al. Who and when should we screen for prostate cancer? Interviews with key opinion leaders. BMC Med. 2015;13:288.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328.
   PubMed Web of Science ®Google Scholar
• Hugosson J. Stopping screening, when and how? Transl Androl Urol. 2018;7:46–53.
   PubMed Web of Science ®Google Scholar
• Carlsson S, Assel M, Ulmert D, et al. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. Eur Urol. 2017;71:46–52.
   PubMed Web of Science ®Google Scholar
• Gronberg H, Adolfsson J, Aly M, et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015;16:1667–1676.
   PubMed Web of Science ®Google Scholar
• Randazzo M, Beatrice J, Huber A, et al. A "PSA pyramid" for men with initial prostate-specific antigen </=3 ng/ml: a plea for individualized prostate cancer screening. Eur Urol. 2015;68:591–597.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246.
   PubMed Web of Science ®Google Scholar
• Bratt O, Lilja H. Serum markers in prostate cancer detection. Curr Opin Urol. 2015;25:59–64.
   PubMed Web of Science ®Google Scholar
• Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–732.
   PubMed Web of Science ®Google Scholar
• Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.
   PubMed Web of Science ®Google Scholar
• Harrell FEJ. Quantifying Predictive Ability. Regression Modeling Strategies. New York: Springer Science; 2001. p. 492–4.
   Google Scholar
• Weight CJ, Kim SP, Jacobson DJ, et al. Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort. Urology 2013;82:1211–1217.
   PubMed Web of Science ®Google Scholar
• Carlsson S, Assel M, Sjoberg D, et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ. 2014;348:g2296
   PubMedGoogle Scholar
• Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. Bmj. 2013;346:f2023
   PubMedGoogle Scholar
• Sasaki M, Ishidoya S, Ito A, et al. Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less. Urology. 2014;84:1163–1167.
   PubMed Web of Science ®Google Scholar
• Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046–1055.
   PubMed Web of Science ®Google Scholar
• Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767–1777.
   PubMed Web of Science ®Google Scholar
• Roddam AW, DuffyMJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386–399.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004;171:2239–2244.
   PubMedGoogle Scholar
• Finne P, Auvinen A, Maattanen L, et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol. 2008;54:362–370.
   PubMed Web of Science ®Google Scholar
• Vedder MM, de Bekker-Grob EW, Lilja HG, et al. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol. 2014;66:1109–1115.
   PubMed Web of Science ®Google Scholar
• Grenabo Bergdahl A, Wilderang U, Aus G, Carlsson S, Damber JE, Franlund M, et al. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Goteborg Randomised Screening Trial. Eur Urol. 2016;70 (4):566–573. doi:10.1016/j.eururo.2015.12.006
   PubMed Web of Science ®Google Scholar